Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

White paper on Ivermectin as a potential therapy for COVID-19

Vora et al., Indian Journal of Tuberculosis, doi:10.1016/j.ijtb.2020.07.031
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
Panel review of ivermectin reporting that "ivermectin in the dose of 12mg BD alone or in combination with other therapy for 5–7 days may be considered as safe therapeutic option for mild moderate or severe cases of Covid-19 infection. It is cost effective especially when the other drugs are very costly & not easily available".
Reviews covering ivermectin for COVID-19 include1-38.
Vora et al., 31 Jul 2020, peer-reviewed, 4 authors.
This PaperIvermectinAll
White paper on Ivermectin as a potential therapy for COVID-19
Agam Vora, V K Arora, D Behera, Surya Kant Tripathy
Indian Journal of Tuberculosis, doi:10.1016/j.ijtb.2020.07.031
A group of senior doctors with vast clinical experience met on 19th July'20 under the aegis of Academy of Advanced Medical Education. The panel looked at Ivermectin, one of the old molecule and evaluated it's use in COVID 19 (Novel Coronavirus Disease 2019) management. After critical panel discussion, all the attending doctors came to a conclusion that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability and good tolerability and safety.
Author's contributions All authors provided critical feedback and contributed to the final manuscript. Declaration of Competing Interest The authors have none to declare.
References
Banerjee, Nandy, Dalai, Ahmed, The battle against COVID 19 pandemic: what we need to know before we "test fire, Ivermectin. Drug Res, doi:10.1055/a-1185-8913
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS
Cherian, Agrawal, Basu, Abraham, Gangakhedkar et al., Perspectives for repurposing drugs for the coronavirus disease 2019, Indian J Med Res, doi:10.4103/ijmr.IJMR_585_20
Chowdhury, Shahbaz, Karim, Islam, Dan et al., A comparative observational study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
David, What is the role of antiparasitic drug ivermectin in the treatment of corona virus disease
Gupta, Sahoo, Singh, Ivermectin: potential candidate for the treatment of Covid 19, Braz J Infect Dis
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol, doi:10.1177/009127002401382731
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Mah Evas, Tran, Roumier, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ, doi:10.1136/bmj.m1844
Pal, Yadav, COVID-19 pandemic in India: present scenario and a steep climb ahead, J Prim Care Commun Health, doi:10.1177/2150132720939402
Patel, Desai, Grainger, Mehra, Usefulness of Ivermectin in COVID-19 Illness
Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19, doi:10.1101/2020.06.06.20124461
Romagnoli, Peris, Gaudio, Geppetti, SARS-CoV-2 and COVID-19: from the Bench to the bedside, Physiol Rev, doi:10.1152/physrev.00020.2020
Sharun, Dhama, Patel, Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Ann Clin Microbiol Antimicrob, doi:10.1186/s12941-020-00368-w
Sinhaa, Sehgalb, Sehgala, Ivermectin: is it to Be a potent therapeutic option for COVID-19?, Clin Infect Immun, doi:10.14740/cii106
Vora, Arora, Behera Academy of Advanced Medical Education
{ 'indexed': { 'date-parts': [[2023, 10, 12]], 'date-time': '2023-10-12T01:28:25Z', 'timestamp': 1697074105687}, 'reference-count': 19, 'publisher': 'Elsevier BV', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2020, 7, 1]], 'date-time': '2020-07-01T00:00:00Z', 'timestamp': 1593561600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [ { 'DOI': '10.13039/100007028', 'name': 'Helmsley Charitable Trust', 'doi-asserted-by': 'publisher'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 7]]}, 'DOI': '10.1016/j.ijtb.2020.07.031', 'type': 'journal-article', 'created': {'date-parts': [[2020, 8, 18]], 'date-time': '2020-08-18T12:33:38Z', 'timestamp': 1597754018000}, 'page': '448-451', 'source': 'Crossref', 'is-referenced-by-count': 17, 'title': 'White paper on Ivermectin as a potential therapy for COVID-19', 'prefix': '10.1016', 'volume': '67', 'author': [ {'given': 'Agam', 'family': 'Vora', 'sequence': 'first', 'affiliation': []}, {'given': 'V.K.', 'family': 'Arora', 'sequence': 'additional', 'affiliation': []}, {'given': 'D.', 'family': 'Behera', 'sequence': 'additional', 'affiliation': []}, {'given': 'Surya Kant', 'family': 'Tripathy', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijtb.2020.07.031_bib1', 'doi-asserted-by': 'crossref', 'DOI': '10.1177/2150132720939402', 'article-title': 'COVID-19 pandemic in India: present scenario and a steep climb ahead', 'volume': '11', 'author': 'Pal', 'year': '2020', 'journal-title': 'J Prim Care Commun Health'}, { 'issue': '2', 'key': '10.1016/j.ijtb.2020.07.031_bib2', 'doi-asserted-by': 'crossref', 'first-page': '51', 'DOI': '10.14740/cii106', 'article-title': 'Ivermectin: is it to Be a potent therapeutic option for COVID-19?', 'volume': '5', 'author': 'Sinhaa', 'year': '2020', 'journal-title': 'Clin Infect Immun'}, { 'issue': '1', 'key': '10.1016/j.ijtb.2020.07.031_bib3', 'doi-asserted-by': 'crossref', 'first-page': '23', 'DOI': '10.1186/s12941-020-00368-w', 'article-title': 'Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19', 'volume': '19', 'author': 'Sharun', 'year': '2020', 'journal-title': 'Ann Clin Microbiol Antimicrob'}, { 'key': '10.1016/j.ijtb.2020.07.031_bib4', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in\xa0vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ijtb.2020.07.031_bib5', 'article-title': 'The battle against COVID 19 pandemic: what we need to know before we ' '“test fire” Ivermectin', 'author': 'Banerjee', 'year': '2020', 'journal-title': 'Drug Res (Stuttg)'}, {'key': '10.1016/j.ijtb.2020.07.031_bib6', 'author': 'Chowdhury'}, { 'issue': '2 & 3', 'key': '10.1016/j.ijtb.2020.07.031_bib8', 'doi-asserted-by': 'crossref', 'first-page': '160', 'DOI': '10.4103/ijmr.IJMR_585_20', 'article-title': 'Perspectives for repurposing drugs for the coronavirus disease 2019', 'volume': '151', 'author': 'Cherian', 'year': '2020', 'journal-title': 'Indian J Med Res'}, { 'key': '10.1016/j.ijtb.2020.07.031_bib9', 'first-page': 'm2328', 'article-title': 'Clinical efficacy of hydroxychloroquine in patients with covid-19 ' 'pneumonia who require oxygen: observational comparative study using ' 'routine care data', 'volume': '369', 'author': 'Mahévas', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.ijtb.2020.07.031_bib10', 'article-title': 'Targeted Update: safety and efficacy of hydroxychloroquine or ' 'chloroquine for treatment of COVID-19', 'year': '2020', 'journal-title': 'WHO'}, { 'key': '10.1016/j.ijtb.2020.07.031_bib11', 'doi-asserted-by': 'crossref', 'DOI': '10.1152/physrev.00020.2020', 'article-title': 'SARS-CoV-2 and COVID-19: from the Bench to the bedside', 'volume': '100', 'author': 'Romagnoli', 'year': '2020', 'journal-title': 'Physiol Rev'}, { 'issue': '20', 'key': '10.1016/j.ijtb.2020.07.031_bib12', 'first-page': '30081', 'article-title': 'Ivermectin: potential candidate for the treatment of Covid 19', 'volume': 'S1413–8670', 'author': 'Gupta', 'year': '2020', 'journal-title': 'Braz J Infect Dis'}, {'key': '10.1016/j.ijtb.2020.07.031_bib13', 'author': 'Clinical Trials Registry- India'}, { 'issue': '10', 'key': '10.1016/j.ijtb.2020.07.031_bib14', 'doi-asserted-by': 'crossref', 'first-page': '1122', 'DOI': '10.1177/009127002401382731', 'article-title': 'Safety, tolerability, and pharmacokinetics of escalating high doses of ' 'ivermectin in healthy adult subjects', 'volume': '42', 'author': 'Guzzo', 'year': '2002', 'journal-title': 'J Clin Pharmacol'}, {'key': '10.1016/j.ijtb.2020.07.031_bib15', 'author': 'Drugs@FDA: FDA-Approved Drugs'}, {'key': '10.1016/j.ijtb.2020.07.031_bib18', 'author': 'Cennimo'}, {'key': '10.1016/j.ijtb.2020.07.031_bib19', 'author': 'Rajter'}, { 'key': '10.1016/j.ijtb.2020.07.031_bib20', 'series-title': 'Usefulness of Ivermectin in COVID-19 Illness', 'author': 'Patel', 'year': '2020'}, { 'key': '10.1016/j.ijtb.2020.07.031_bib22', 'article-title': 'To study the effectiveness of Ivermectin with standard of care ' 'treatment versus standard of care treatment for COVID 19 cases', 'year': '2019', 'journal-title': 'A Pilot Study'}, { 'key': '10.1016/j.ijtb.2020.07.031_bib23', 'first-page': '1', 'article-title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 ' 'complementary regimen', 'author': 'Heidary', 'year': '2020', 'journal-title': 'J Antibiot (Tokyo)'}], 'container-title': 'Indian Journal of Tuberculosis', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0019570720301025?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0019570720301025?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 11, 7]], 'date-time': '2022-11-07T21:04:21Z', 'timestamp': 1667855061000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0019570720301025'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 7]]}, 'references-count': 19, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2020, 7]]}}, 'alternative-id': ['S0019570720301025'], 'URL': 'http://dx.doi.org/10.1016/j.ijtb.2020.07.031', 'relation': {}, 'ISSN': ['0019-5707'], 'subject': [], 'container-title-short': 'Indian Journal of Tuberculosis', 'published': {'date-parts': [[2020, 7]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit